Robert Kauffman, MD
Reproductive Endocrinology · Amarillo, TXNPI 1841222049
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,616 of the $46,474 with a category attached, or 93.9%. 11 manufacturers reported payments, led by Organon at 50.2% of the total. Reporting peaked in 2023 at $20,818 and has fallen 78.1% since, to $4,558 in 2025. Among reproductive endocrinology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $603.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$23K
- Astellas Pharma US Inc$18K
- Merck$5K
- Coopersurgical, Inc.$184
- Mayne Pharma Commercial LLC$79
- AbbVie$72
- plus $163 from 5 others
Across 3 payments — averaging $4375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$13K
What the payments were for
- Speaking & faculty fees$43,61694%
- Travel & lodging$1,8374%
- Food & beverage$1,0212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 34 | $23,352 |
| Astellas Pharma US Inc | 16 | $18,002 |
| Merck | 11 | $4,621 |
| Coopersurgical, Inc. | 3 | $184 |
| Mayne Pharma Commercial LLC | 1 | $79 |
| AbbVie | 4 | $72 |
| Bayer | 3 | $49 |
| Baudax Bio Inc. | 2 | $41 |
| Heron Therapeutics, Inc. | 1 | $41 |
| Viiv Healthcare Company | 1 | $17 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$25,532
- Veozah$17,337
- Advincula Delineator Uterine Manipulator$122
How this compares
$46,474 in reported general payments places this provider in the 95th percentile of 142 reproductive endocrinology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol (Twice Weekly)Estradiol | 17 | $1,995 |
| Estradiol | 26 | $1,421 |
| Clobetasol Propionate | 11 | $278 |
| Tolterodine Tartrate | 12 | $244 |
| Dicyclomine Hcl | 12 | $234 |
| Levothyroxine Sodium | 15 | $84 |
Paid to pharmacies, not to this prescriber.
Other reproductive endocrinology in Amarillo
- Randall DunnHouston$234K
- Jason GriffithSpring$145K
- Kaylen SilverbergAustin$127K
- Matthew RetzloffSan Antonio$120K
- Kevin DoodyBedford$118K
- Kathleen DoodyBedford$49K
- Satin PatelDallas$32K
- Craig WitzHouston$32K
- Jason YehHouston$31K
- Vicky SchnellWebster$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.